Association between resistin levels and all-cause and cardiovascular mortality: A new study and a systematic review and meta-analysis

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Fontana, Andrea ^a   Spadaro, Sara ^b,c   Copetti, Massimiliano ^a   Spoto, Belinda ^d   Salvemini, Lucia ^a   Pizzini, Patrizia ^d   Frittitta, Lucia ^b   Mallamaci, Francesca ^d   Pellegrini, Fabio ^a   Trischitta, Vincenzo ^a,e   Menzaghi, Claudia ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c SCUOLA SUPERIORE DI CATANIA   (Italy)

^d CNR   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RESISTIN;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HIGH RISK PATIENT; HUMAN; INCIDENCE; PREDICTION; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; AGED; BLOOD; COMPLICATION; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; RESISTIN;

EID: 84925455240     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120419     Document Type: Review

References (27)

1. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-939. PMID: 15710760
2. Langheim S, Dreas L, Veschini L, Maisano F, Foglieni C, Ferrarello S, et al. Increased expression and secretion of resistin in epicardial adipose tissue of patients with acute coronary syndrome. American journal of physiology 2010; 298: H746-753. doi: 10.1152/ajpheart.00617.2009 PMID: 20061546
3. Pischon T, Bamberger CM, Kratzsch J, Zyriax BC, Algenstaedt P, Boeing H, et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005; 13: 1764-1771. PMID: 16286524
4. On YK, Park HK, Hyon MS, Jeon ES. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J 2007; 71: 868-873. PMID: 17526982
5. Ohmori R, Momiyama Y, Kato R, Taniguchi H, Ogura M, Ayaori M, et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. Journal of the American College of Cardiology 2005; 46: 379-380. PMID: 16022972
6. Tsukahara T, Nakashima E, Watarai A, Hamada Y, Naruse K, Kamiya H, et al. Polymorphism in resistin promoter region at-420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 2009; 84: 179-186. doi: 10.1016/j.diabres.2008. 10.021 PMID: 19269054
7. Cheng JM, Akkerhuis KM, Battes LC, van Vark LC, Hillege HL, Paulus WJ, et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. European Journal of Heart Failure 2013; 15: 1350-1362. doi: 10.1093/eurjhf/hft106 PMID: 23845797
8. Efstathiou SP, Tsiakou AG, Tsioulos DI, Panagiotou TN, Pefanis AV, Achimastos AD, et al. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta 2007; 378: 78-85. PMID: 17173885
9. Lubos E, Messow CM, Schnabel R, Rupprecht HJ, Espinola-Klein C, Bickel C, et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007; 193: 121-128. PMID: 16814296
10. Pilz S, Weihrauch G, Seelhorst U, Wellnitz B, Winkelmann BR, Boehm BO, et al. Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin Endocrinol (Oxf) 2007; 66: 380-386. PMID: 17302872
11. Lee SH, Ha JW, Kim JS, Choi EY, Park S, Kang SM, et al. Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from infarction prognosis study registry. Coron Artery Dis 2009; 20: 33-39. doi: 10.1097/MCA.0b013e328318ecb0 PMID: 18997620
12. Zhang MH, Na B, Schiller NB, Whooley MA. Association of resistin with heart failure and mortality in patients with stable coronary heart disease: data from the heart and soul study. J Card Fail 2011; 17: 24-30. doi: 10.1016/j.cardfail.2010.08.007 PMID: 21187261
13. Menzaghi C, Bacci S, Salvemini L, Mendonca C, Palladino G, Fontana A, et al. Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes. PLoS One 2013; 8: e64729. doi: 10.1371/journal.pone.0064729 PMID: 23755138
14. Silva AP, Fragoso A, Silva C, Viegas C, Tavares N, Guilherme P, et al. What is the role of apelin regarding cardiovascular risk and progression of renal disease in type 2 diabetic patients with diabetic nephropathy? Biomed Res Int 2013; 2013: 247649. doi: 10.1155/2013/247649 PMID: 24089668
15. Spoto B, Mattace-Raso F, Sijbrands E, Pizzini P, Cutrupi S, D'Arrigo G, et al. Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients. Nephrol Dial Transplant 2013;28 Suppl 4: : iv181-187.
16. Menzaghi C, Xu M, Salvemini L, De Bonis C, Palladino G, Huang T, et al. Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism. Cardiovasc Diabetol 2014; 13: 130 "In press". doi: 10.1186/s12933-014-0130-y PMID: 25200659
17. Menzaghi C, Coco A, Salvemini L, Thompson R, De Cosmo S, Doria A, et al. Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. The Journal of clinical endocrinology and metabolism 2006; 91: 2792-2795. PMID: 16670163
18. Hartemink N, Boshuizen HC, Nagelkerke NJ, Jacobs MA, van Houwelingen HC. Combining risk estimates from observational studies with different exposure cutpoints: a meta-analysis on body mass index and diabetes type 2. American journal of epidemiology 2006; 163: 1042-1052. PMID: 16611666
19. Il'yasova D, Hertz-Picciotto I, Peters U, Berlin JA, Poole C. Choice of exposure scores for categorical regression in meta-analysis: a case study of a common problem. Cancer causes & control: CCC 2005; 16: 383-388.
20. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30. PMID: 3678409
21. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002; 21: 589-624. PMID: 11836738
22. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002. doi: 10.1136/bmj.d4002 PMID: 21784880
23. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in metaanalyses: a large survey. CMAJ 2007; 176: 1091-1096. PMID: 17420491
24. Cho Y, Lee SE, Lee HC, Hur J, Lee S, Youn SW, et al. Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery. J Am Coll Cardiol 2011; 57: 99-109. doi: 10.1016/j.jacc.2010.07.035 PMID: 21185508
25. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 2007; 30: 1292-1293. PMID: 17290036
26. D'Agostino R, Nam BH. Evaluation of the performance of survival analysis models: discrimination and calibration measures. Handbook of Statistics, vol 23 Elsevier Science BV, 2004.
27. De Cosmo S, Copetti M, Lamacchia O, Fontana A, Massa M, Morini E, et al. Development and Validation of a Predicting Model of All-Cause Mortality in Patients With Type 2 Diabetes Mellitus. Diabetes Care 2013; 36:2830-2835. doi: 10.2337/dc12-1906 PMID: 23637348